Clinical Trials
3 trialsNCT00792506 2022-02-02
Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma
Italfarmaco
Phase 2 Terminated
NCT00496431 2022-01-27
phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients
Italfarmaco
Phase 1/2 Terminated
NCT00792831 2022-01-27
Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic Leukemia
Italfarmaco
Phase 2 Terminated